21 CFR 522.147
§ 522.147 Atipamezole.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 522.147, § 522.147 Atipamezole, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87389
- Permanent ID
ys:prov:87389@1- SHA-256
98803667cf225d8b53d886508ff63f7963d0680010e673847fa87519e8020d52
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications. Each milliliter of solution contains 5.0 milligrams atipamezole hydrochloride.
(b) Sponsors. See Nos. 015914, 052483, 068504, 069043, and 086101 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. Administer 3,750 mcg/m 2 intramuscularly for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride and 5,000 mcg/m 2 intramuscularly for the reversal of intramuscular dexmedetomidine hydrochloride or medetomidine hydrochloride.
(2) Indications for use. For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.